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Abstract Pharmacokinetic properties of a drug, and selection and correct usage of an appropriate delivery device, are 
factors that can affect the outcome of inhaled therapyThe use of nebulization can overcome problems that are associated 
with other delivery systems used for inhalation therapyThe objective of this open, randomized, single-dose study was to 
compare the systemic exposure and safety of beclometasone dipropionate (BDP) suspension for nebulization with BDP 
via metered-dose inhaler (MDI) in healthy subjects. Following a run-in period to assess basal 24-h serum cortisol levels 
and cotiisol urinary excretion, I2 healthy males were administered BDP I 600 pg given via MDI and were then randomized 
to receive a single dose of either I600 pg (n=6) or 3200 pg BDP (n=6) suspension for nebulization given via a nebulizev: 
Results with respect to systemic exposure to beclometasone-I7-monopropionate (BI7MP) (the active metabolite of 
BDP) and systemic effects on the hypothalamic-pituitary-adrenal (HPA) axis were determined by evaluation of a number 
of pharmacokinetic parameters for plasma B I7MP and serum and urinary cortisol, respectively A statistically significantly 
greater peak plasma concentration (C,d of B I7MP was reported with BDP via MDI ( I587 pg ml-l) compared with BDP 
I 600 pg (455 pg ml-l) and BDP 3200 pg suspensions for nebulization (758 pg ml-l), and was achieved more rapidly (T,d 
(I .3 h, 3 h, and 2.5 h, respectively). In addition, elimination half-life (t&) was statistically significantly shorter with BDP via 
MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with I600 pg and 3200 pg, 
respectively), as was mean residence time (MRT) (5.4 h, I I . I h, and IO.0 h, respectively).Total systemic exposure to B I7MP 
(as determined by the area under the concentration-time curve: AUC,) was comparable for BDP via MDI 
(6883 pg ml-1 h-1) and BDP 3200 pg suspension for nebulization (820 I pg ml-1 h-l), but significantly greater than with BDP 
I 600 pg suspension for nebulization (4870 pg ml -1 ; WO.05 vs BDP via MDI). All treatments were well tolerated, and no 
significant differences were found between them with respect to the serum or urinary cortisol pharmacokinetic 
parameters assessed. In conclusion, the results of this study demonstrate that BDP suspension for nebulization 3200 pg 
given via a nebulizer and BDP I600 pg given via an MDI are equivalent in terms of systemic exposure to B I7MP and 
systemic effects on the HPA axis, with BDP suspension for nebulization having a potentially more prolonged activity It 
confirms that use of a double dose of BDP suspension for nebulization administered by nebulizer compared with BDP 
given via metered-dose inhalation is justified and poses no risk with regard to safety. 
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INTRODUCTION and metabolized to beclometasone in the systemic 
circulation. Plasma levels of unchanged BDP are negligible. 
Beclometasone dipropionate (BDP) is a prodrug with In addition to receptor affinity, prolonged high local 
weak glucocorticoid receptor-binding affinity and exhibits concentrations of inhaled steroids in the airways are 
high topical and low systemic activity. Following necessary for effective anti-asthma efficacy and airways 
inhalation, BDP is primarily hydrolysed in the lung (I) to selectivity. It has been demonstrated, as observed with 
the topically active metabolite beclometasone- I7- budesonide (2) that BI 7MP within the airways may 
monopropionate (BI 7MP). In turn, BI 7MP is absorbed produce highly liphophilic esters with prolonged 
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retention in the lung tissues (3).These liphophilic esters 
are stored and then gradually hydrolysed, and free 
B I7MP is subsequently regenerated. The reversible 
conjugates may prolong the local anti-inflammatory 
activity of BDP and suggest effectiveness of once-daily 
administration when used for mild asthma. 
As well as the pharmacokinetic properties of a drug, the 
selection and correct usage of a suitable inhaler device can 
influence the delivery of inhaled drugs and their 
subsequent systemic bioavailability,and hence the results of 
treatment (4,5). Using nebulization for the administration 
of inhaled steroid therapy can overcome co-ordination and 
inspiratory problems that may arise with metered-dose 
and dry-powder inhalers, respectively (6,7). 
The purpose of this study was to compare the 
systemic exposure to B I7MP and safety associated with 
two different doses of a new formulation of BDP 
suspension for nebulization administered via a nebulizer 
and BDP administered via a metered-dose inhaler (MDI) 
in healthy male volunteers. 
MATERIALS AND METHODS 
Healthy male volunteers, aged 19-43 years, who were 
non-smokers and in good physical and mental health, and 
with vital sign values within the normal range, 
participated in the study. 
Study design 
This was an open, randomized, single-dose study. 
Following a run-in period to evaluate basal serum 
cortisol profile and cortisol urinary excretion, subjects 
were given BDP 1600 ,ug via MDI (eight inhalations) 
(Becotidea 200 pg dose-l, Allen & Hanburys, U.K.) and 
then assigned by randomization to receive BDP 
suspension for nebulization (Clenil A@, 800 pg vial-‘, 
Chiesi Farmaceutici, Italy) I600 pg (two vials) inhaled 
over a I5-min period or 3200 pg (four vials) inhaled over 
two I5-min periods.The suspension for nebulization was 
administered using a Pari Boy@ compressor and an LC 
Plus@ nebulizer (Pari Turbo Boy@, Pari, Germany). All 
subjects were instructed in the correct usage of the MDI 
and of nebulizers, and first practised inhaling using 
placebos. The MDI inhaler was vigorously shaken and 
primed before drug administration, and after each 
inhalation subjects held their breath for IO s. A I -week 
washout period separated the treatments, and each 
treatment was administered at approximately 8 a.m.The 
use of concomitant medications in the I4 days preceding 
the study (2 months for enzyme-inducing drugs), and 
consumption of alcohol, xanthine-containing beverages, 
or grapefruit in the 48 h preceding each study period 
(until 24 h after), were excluded. 
A total of I8 plasma samples were taken over 24 h 
after drug administration for determination of plasma 
BDP and B I7MP levels by means of validated chromato- 
graphic methods (LC-MS/MS), with a quantitation limit of 
20 pg ml-‘, at the Phoenix International Life Sciences 
Laboratories (Canada). 
A total of IO serum samples were taken over 24 h 
during the run-in period and after drug administration to 
measure serum cortisol levels, and urine was collected 
over 24 h during the same periods to measure cortisol 
urinary excretion. Cortisol in both serum and urine was 
determined by means of a validated radioimmunoassay 
(RIA) method, with a quantitation limit of IO ng ml-‘, at 
SGS-Biopharma Laboratories (Belgium). B I7MP and 
urinary cortisol pharmacokinetic parameters were 
calculated using validated SAS@ version 6. I2 procedures, 
and serum cortisol pharmacokinetic parameters using 
WinNonlin Professional 3.0 procedures. The study was 
approved by the local Medical Ethics Committee of 
Antwerp (Belgium) and subjects gave their written 
informed consent. The study was performed in 
accordance with the principles stated in the Declaration 
of Helsinki. 
Assessments 
The main variables assessed were systemic exposure to 
B I7MP by measuring plasma BDP and B I7MP levels, and 
safety by examining adverse events and systemic effects 
on the HPA axis. 
Various pharmacokinetic parameters of plasma B I 7MP 
were calculated: C,, andT,, (value and time of maximum 
concentration without interpolation, respectively), AUC, 
(area under the concentration-time curve calculated 
using the trapezoidal method with linear interpolation, 
from t=O to t=last measurable data point),AUC, (area 
under the concentration-time curve extrapolated to 
infinity), tX,, ( I e imination half-life), and MRT (mean 
residence time). 
Potential suppression of the hypothalamic-pituitary- 
adrenal (HPA) axis was assessed by calculating various 
pharmacokinetic parameters of serum cortisol over a 
24-h period, namely A,,,= (maximum deviation from run- 
in), tam,, (time of maximum deviation), and AUCA (area 
under the curve of the deviations from run-in), and of 
cortisol urinary excretion, namely Ae (24-h urinary 
excretion), Aenorm (%) (24-h urinary excretion 
normalized for cortisol excretion during run-in), and 
Ae/Aecreat (24-h urinary excretion normalized for 
creatinine excretion). 
Statistical analysis 
For all B I7MP and cortisol pharmacokinetic parameters, 
statistical analysis was carried out using validated SAS@ 
version 6. I2 procedures. The main pharmacokinetic 
parameters for BI 7MP (C,,,, AUC,, AUC,, tXe,, and 
MRT) and cortisol (A,,,, AUCA, Ae, Aenorm (%), and 
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Ae/Aecreat) were statistically compared according to 
the ANOVA (analysis of variance) using the SAS@/STAT 
GLM procedure. T,, values were compared according 
to the non-parametric Wilcoxon scores (Rank Sum) test. 
RESULTS 
Patient population 
Of the I2 subjects who entered the study, one 
demonstrated atypic serum cortisol and urinary cortisol 
excretion profiles following BDP administration via MDI, 
possibly related to a gastrointestinal disorder 
experienced overnight. The BDP MDI group was 
therefore made up of I I subjects for cortisol 
assessments, and the two BDP nebulization groups of six 
patients each for all assessments. Subject demography at 
baseline is reported inTable I. 
Evaluation of systemic exposure 
Since plasma levels of unchanged BDP were very low and 
undetectable shortly after inhalation, pharmacokinetic 
parameter calculations were only carried out for B I7MP 
Following the administration of BDP via MDI, plasma 
concentrations of BI 7MP increased fairly rapidly, 
resulting in a significantly higher peak and shorter time to 
peak than observed with either dose of BDP suspension 
for nebulization (Table 2 and Figure I). Peak plasma con- 
1600- 
-I- BDP via MD1 1600 ,ug 
--a--- BDP suspension for nebuliration 1600 pig 
- C - BDP suspension for nebuliration 3200 pg 
0 3 6 9 12 15 18 21 24 
Time(b) 
FIGURE I. B I7MP plasma profile (geometric means) in healthy 
male volunteers after single-dose administration of BDP 
suspension for nebulization or BDP administered via MDI. 
centrations with BDP I600 pg and 3200 ug suspensions 
for nebulization were one-third and one-half lower, 
respectively, than those seen with BDP administered via 
MDI. Furthermore, elimination half-life was significantly 
prolonged with both doses of BDP suspension for 
nebulization vs BDP via MDI.Total systemic exposure to 
BI 7MP as indicated by AUC, values, was significantly 
lower (by approximately 30%) with BDP 1600 /tg 
suspension for nebulization than with BDP via MDI, while 
there was no significant difference between BDP via MDI 
and BDP 3200 pg suspension for nebulization (Table 2). 
In addition, MRT values were significantly greater with 
both doses of BDP suspension for nebulization than with 
BDP administered via MDI. 
Evaluation of safety 
Safety data showed that all treatments were well 
tolerated and had a comparable safety profile. Adverse 
events reported during the study were mild in severity. 
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FIGURE 2. Serum cortisol profile in healthy male volunteers 
during run-in and after single-dose administration of BDP 
suspension for nebulization administered via a nebulizer or BDP 
administered via MDI. 
During the run-in period, serum cortisol 
concentrations dropped from I22 ng ml-r at 8.00 a.m. to 
17 ng ml-r at midnight before increasing again until 
8.00 am the following morning.With all BDP treatments, 
levels fell more rapidly after administration than during 
the run-in, such that after 6 h they were below 25 ng ml-r 
(compared with just over 75 ng ml-’ during the run-in) 
(Figure 2). From 6 h to I6 h after administration, serum 
cortisol levels remained fairly stable at a minimum value 
and then increased in a similar manner for all treatments 
to the run-in period until 8.00 a.m. the following day. No 
significant differences were found between the 
treatments with respect to any of the pharmacokinetic 
parameters evaluated for serum cortisol (Table 3). 
Cortisol urinary excretion over 24 hours was in the 
normal range (20-90 pg 24 h-r according to the RADIM 
RIA lkit) in all subjects except for one, who had values of 
18.8 pg 24 h-l with BDP via MDI and 13.8 pg 24 h-l with 
BDP 3200 yg suspension for nebulization. Cortisol 
urinary excretion normalized for creatinine was virtually 
unchanged compared with run-in with BDP 1600 I-18 
suspension nebulization, and approximately IO% and 20% 
lower with BDP 3200 pg suspension for nebulization and 
BDP via MDI, respectively (Table 4 and Figure 3). 
Differences between treatments, however, were not 
statistically significant. Cortisol excretion normalized for 
run-in showed a similar trend, with reductions vs run-in 
of approximately IO%, l7%, and 26% with BDP 1600 p.g 
suspension for nebulization, BDP 3200 pg suspension for 
nebulization, and BDP administered via MDI, respectively 
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FIGURE 3. Urinary cortisol excretion normalized for creatinine 
urinary excretion (Ae/Aecreat) in healthy male volunteers during 
run-in and after single-dose administration of BDP suspension for 
nebulization administered via a nebulizer or BDP administered via 
MDI. 
(Table 4). Again, differences between treatments were 
not statistically significant. 
DISCUSSION 
This study was designed to evaluate the systemic 
exposure to B I7MP and safety associated with single-dose 
administrations of two different dosages of a new 
formulation of BDP suspension given via a nebulizer and 
BDP given via an MDI in healthy volunteers. 
Two previous studies have compared the systemic 
bioavailability of budesonide delivered via nebulizer and 
MDI with conflicting results. One study showed 
considerable suppression of morning plasma cortisol 
levels with high-dose (4 mg) budesonide given via MDI, 
but no effect was seen with the same dose of budesonide 
given via nebulizer (8). Conversely, a second study in 
adult asthmatics showed a clear dose-related effect of 
0.8 mg budesonide delivered via MDI and I mg and 4 mg 
nebulized budesonide on plasma budesonide and plasma 
cortisol levels, that was independent of the device (9). It 
has been suggested that different types of nebulizers may 
influence the amount of drug that is delivered to the 
lungs, and subsequently the drug’s bioavailability (I 0), and 
this may explain the inconsistencies to date. 
The results from this study, using the Pari Turbo Boy@ 
nebulizer, demonstrate significant differences between 
BDP administered via MDI and BDP suspension for 
nebulization with respect to several of the pharmaco- 
kinetic parameters assessed for plasma B I7MP. Admini- 
stration of BDP via MDI was associated with a more 
rapid rise to peak plasma concentrations of B I7MP (thus 
suggesting rapid absorption of BDP and subsequent 
metabolism to B I7MP), greater peak plasma concentra- 
tions of BI 7MP and a notably shorter elimination half-life 
of plasma B I7MP than both the same dose and double 
the dose of BDP suspension for nebulization.The delayed 
peak plasma concentration and prolonged elimination 
half-life of BI 7MP seen with BDP suspension for 
nebulization indicate slow and prolonged absorption of 
BDP from the lung, a hypothesis that is further 
supported by the MRT values of BI 7MP which were 
significantly greater with both dosages of BDP 
suspension for when compared with BDP via MDI. 
Although systemic levels of drugs that exert their topical 
activity in the lungs are important, more in terms of 
safety rather than activity, the prolonged elimination half- 
life and sustained BI 7MP levels noted with BDP 
suspension for nebulization may be related to the 
persistence of BDP at the site of action, thus suggesting 
potentially prolonged activity compared with BDP 
administered via MDI.Total systemic exposure to B I7MP 
noted with BDP via MDI, however, was similar to that 
noted with BDP 3200 pg suspension for nebulization, but 
considerably greater than with BDP I600 ug suspension 
for nebulization. In contrast, no significant differences 
were found between BDP via MDI and BDP suspension 
for nebulization with regard to the safety profile, 
including measures of HPA axis suppression. 
In conclusion, this study demonstrates that the 
systemic exposure to B I7MP and systemic effect on HPA 
axis with BDP 3200 ug given via a nebulizer are 
comparable with those of BDP I600 pg given via an MDI. 
The study also confirms that a double dose of BDP 
administered via a nebulizer compared with an MDI is 
justified, and does not present any additional safety risk 
for the patient. 
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